Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
67407-1-PBS targets VEGFR2/KDR in WB, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | VEGFR2/KDR fusion protein Ag24589 相同性解析による交差性が予測される生物種 |
| Full Name | kinase insert domain receptor (a type III receptor tyrosine kinase) |
| Calculated molecular weight | 1356 aa, 152 kDa |
| Observed molecular weight | 230 kDa |
| GenBank accession number | BC131822 |
| Gene Symbol | KDR |
| Gene ID (NCBI) | 3791 |
| RRID | AB_2882648 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein G purification |
| UNIPROT ID | P35968 |
| Storage Buffer | PBS Only |
| Storage Conditions | Store at -80°C. |
Background Information
KDR, also named as VEGFR-2, FLK1 and CD309, is a receptor for VEGF or VEGFC. KDR which belongs to the protein kinase superfamily, has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. KDR functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. Mutations of this gene are implicated in infantile capillary hemangiomas.